1.19
price up icon1.71%   0.02
after-market After Hours: 1.19
loading
Femasys Inc stock is traded at $1.19, with a volume of 286.11K. It is up +1.71% in the last 24 hours and up +8.18% over the past month. Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics.
See More
Previous Close:
$1.17
Open:
$1.16
24h Volume:
286.11K
Relative Volume:
1.48
Market Cap:
$27.25M
Revenue:
$950.10K
Net Income/Loss:
$-16.69M
P/E Ratio:
-1.4337
EPS:
-0.83
Net Cash Flow:
$-15.16M
1W Performance:
+3.48%
1M Performance:
+8.18%
6M Performance:
+6.25%
1Y Performance:
+51.02%
1-Day Range:
Value
$1.12
$1.20
1-Week Range:
Value
$1.04
$1.25
52-Week Range:
Value
$0.734
$2.40

Femasys Inc Stock (FEMY) Company Profile

Name
Name
Femasys Inc
Name
Phone
770-500-3910
Name
Address
3950 JOHNS CREEK COURT, SUWANEE
Name
Employee
34
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
FEMY's Discussions on Twitter

Compare FEMY with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Medical Instruments & Supplies icon
FEMY
Femasys Inc
1.19 27.25M 950.10K -16.69M -15.16M -0.83
Medical Instruments & Supplies icon
ISRG
Intuitive Surgical Inc
580.18 206.65B 8.35B 2.32B 586.00M 6.41
Medical Instruments & Supplies icon
BDX
Becton Dickinson Co
248.49 68.23B 20.18B 1.71B 3.07B 5.94
Medical Instruments & Supplies icon
ALC
Alcon Inc
92.32 45.66B 9.76B 1.16B 665.00M 2.34
Medical Instruments & Supplies icon
RMD
Resmed Inc
257.65 37.85B 4.81B 1.11B 1.35B 7.55
Medical Instruments & Supplies icon
WST
West Pharmaceutical Services Inc
343.91 24.95B 2.88B 499.60M 321.60M 6.74

Femasys Inc Stock (FEMY) Latest News

pulisher
08:32 AM

Femasys Announces Notices of Intention to Grant for Two New - GlobeNewswire

08:32 AM
pulisher
08:30 AM

Game-Changing Birth Control Tech: Femasys Locks Down Crucial EU Patents for Non-Surgical Alternative - StockTitan

08:30 AM
pulisher
Jan 18, 2025

Femasys gets notice of allowance for new U.S. patent application covering use of Femaseed - MSN

Jan 18, 2025
pulisher
Jan 16, 2025

Femasys Inc. Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment - Marketscreener.com

Jan 16, 2025
pulisher
Jan 16, 2025

Femasys Announces Notice of Allowance for New U.S. Patent - GlobeNewswire

Jan 16, 2025
pulisher
Jan 16, 2025

Femasys Secures Patent Protection for FemaSeed Fertility Treatment Through 2044 - StockTitan

Jan 16, 2025
pulisher
Jan 14, 2025

Femasys Inc. (NASDAQ:FEMY) Stock Position Raised by Geode Capital Management LLC - Defense World

Jan 14, 2025
pulisher
Jan 14, 2025

Femasys (NASDAQ:FEMY) Stock Price Down 2.8% – What’s Next? - Defense World

Jan 14, 2025
pulisher
Dec 23, 2024

HPV Testing & Pap Test Market 2025-2032: Scope, Trend, Expansion Strategies with SWOT Analysis - WICZ

Dec 23, 2024
pulisher
Dec 13, 2024

PharmaCyte Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2024 - Marketscreener.com

Dec 13, 2024
pulisher
Dec 05, 2024

Femasys (NASDAQ:FEMY) Earns “Buy” Rating from HC Wainwright - Defense World

Dec 05, 2024
pulisher
Dec 04, 2024

Femasys shares hold price target with buy rating on HRC Fertility deal - Investing.com Nigeria

Dec 04, 2024
pulisher
Dec 03, 2024

Intratubal Insemination Device Shown Effective, Safe - Streetwise Reports

Dec 03, 2024
pulisher
Dec 03, 2024

Femasys Announces Partnership with HRC Fertility, Esteemed - GlobeNewswire

Dec 03, 2024
pulisher
Dec 02, 2024

Femasys Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Dec 02, 2024
pulisher
Nov 27, 2024

The Latest Analyst Ratings For Femasys - Benzinga

Nov 27, 2024
pulisher
Nov 26, 2024

Femasys Announces Peer-Reviewed Publication of Positive - GlobeNewswire

Nov 26, 2024
pulisher
Nov 26, 2024

Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment - Yahoo Canada Finance

Nov 26, 2024
pulisher
Nov 20, 2024

Femasys price target lowered to $8 from $10 at Chardan - MSN

Nov 20, 2024
pulisher
Nov 15, 2024

Femasys Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance

Nov 15, 2024
pulisher
Nov 14, 2024

Femasys Inc. (FEMY) Quarterly 10-Q Report - Quartzy

Nov 14, 2024
pulisher
Nov 13, 2024

Femasys earnings missed by $0.04, revenue fell short of estimates - Investing.com South Africa

Nov 13, 2024
pulisher
Nov 12, 2024

Femasys Inc. (FEMY) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 12, 2024
pulisher
Nov 12, 2024

Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update - The Manila Times

Nov 12, 2024
pulisher
Nov 12, 2024

Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides - The Bakersfield Californian

Nov 12, 2024
pulisher
Nov 12, 2024

Femasys Sales Surge 127% as Boston IVF Partnership, FDA Clearance Fuel Growth | FEMY Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 07, 2024

Femasys to Exhibit at the Annual AAGL 2024 Global Conference - GlobeNewswire

Nov 07, 2024
pulisher
Nov 06, 2024

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Nov 06, 2024
pulisher
Nov 05, 2024

FEMYFemasys Inc. Latest Stock News & Market Updates - StockTitan

Nov 05, 2024
pulisher
Nov 05, 2024

Femasys Partners with Boston IVF to Expand Access to Novel Fertility Treatment - Femtech Insider

Nov 05, 2024
pulisher
Nov 01, 2024

Femasys secures new patent for FemBloc birth control By Investing.com - Investing.com South Africa

Nov 01, 2024
pulisher
Nov 01, 2024

Femasys issued U.S. patent covering FemBloc device - MSN

Nov 01, 2024
pulisher
Nov 01, 2024

Femasys Issued New U.S. Patent for FemBloc Permanent Birth Control - MPO-mag

Nov 01, 2024
pulisher
Nov 01, 2024

Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control - GlobeNewswire

Nov 01, 2024
pulisher
Nov 01, 2024

Femasys secures new patent for FemBloc birth control - Investing.com

Nov 01, 2024
pulisher
Nov 01, 2024

The 10 Best Booths from ASRM 2022 - Exhibitor Online

Nov 01, 2024
pulisher
Oct 31, 2024

Femasys (NASDAQ:FEMY) Has Debt But No Earnings; Should You Worry? - Simply Wall St

Oct 31, 2024
pulisher
Oct 31, 2024

Femasys Announces Partnership with Boston IVF, Prominent Network of Fertility Centers, to Offer FemaSeed - GlobeNewswire

Oct 31, 2024
pulisher
Oct 29, 2024

Femasys Advances in Women’s Health Innovation - TipRanks

Oct 29, 2024
pulisher
Oct 10, 2024

Femasys to Exhibit at ASRM 2024 and Participate in the Congress’ KEEPR Education Program - GlobeNewswire

Oct 10, 2024
pulisher
Oct 08, 2024

Femasys to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit - The Manila Times

Oct 08, 2024
pulisher
Oct 02, 2024

Femasys Receives Second Order from Spain Partners After - GlobeNewswire

Oct 02, 2024
pulisher
Oct 02, 2024

Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments - StockTitan

Oct 02, 2024

Femasys Inc Stock (FEMY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$22.22
price up icon 3.40%
$72.17
price up icon 1.06%
$225.36
price up icon 0.41%
medical_instruments_supplies BAX
$33.10
price up icon 0.98%
medical_instruments_supplies COO
$98.10
price up icon 0.10%
medical_instruments_supplies WST
$343.91
price up icon 1.28%
Cap:     |  Volume (24h):